TTRX
Turn Therapeutics Inc.
Biotechnology
Market Cap$112M
5Y Perf.-11.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TTRX vs KYMR
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$6.91B
5Y Perf.+14.0%
TTRX vs KYMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TTRX | KYMR |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $112M | $6.91B |
| Revenue (TTM) | — | $51M |
| Net Income (TTM) | $-2M | $-315M |
| Gross Margin | — | 33.2% |
| Operating Margin | — | -7.0% |
| Total Debt | $121K | $82M |
| Cash & Equiv. | $873K | $357M |
Quick Verdict: TTRX vs KYMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KYMR leads in 3 of 5 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Turn Therapeutics Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
TTRX
Turn Therapeutics Inc.
The Quality Compounder
TTRX is the clearest fit if your priority is quality.
- 1.4% margin vs KYMR's -6.1%
Best for: quality
KYMR
Kymera Therapeutics, Inc.
The Income Pick
KYMR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.15
- 154.4% 10Y total return vs TTRX's -45.8%
- Lower volatility, beta 1.15, Low D/E 5.2%, current ratio 10.47x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | TTRX | 1.4% margin vs KYMR's -6.1% |
| Stability / Safety | KYMR | Beta 1.15 vs TTRX's 1.45 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KYMR | +190.7% vs TTRX's -45.8% |
| Efficiency (ROA) | KYMR | -22.3% ROA vs TTRX's -87.1% |
TTRX vs KYMR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKYMRLAGGINGTTRX
TTRXTurn Therapeutics Inc.
0leads
KYMRKymera Therapeutics, …
3leads
6 Total Categories
CATEGORYLEADERvs TTRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
—
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KYMR4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
KYMR6/6
Risk & VolatilityBeta, volatility, and downside exposure
KYMR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
| Metric | TTRXTurn Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | — | $51M |
| EBITDAEarnings before interest/tax | — | -$352M |
| Net IncomeAfter-tax profit | — | -$315M |
| Free Cash FlowCash after capex | — | -$244M |
| Gross MarginGross profit ÷ Revenue | — | +33.2% |
| Operating MarginEBIT ÷ Revenue | — | -7.0% |
| Net MarginNet income ÷ Revenue | — | -6.1% |
| FCF MarginFCF ÷ Revenue | — | -4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +55.5% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +13.4% |
Insufficient data to determine a leader in this category.
Valuation Metrics
Insufficient data to determine a leader in this category.
Valuation Metrics
| Metric | TTRXTurn Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| Market CapShares × price | $112M | $6.9B |
| Enterprise ValueMkt cap + debt − cash | $111M | $6.6B |
| Trailing P/EPrice ÷ TTM EPS | — | -22.93x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 176.26x |
| Price / BookPrice ÷ Book value/share | — | 4.52x |
| Price / FCFMarket cap ÷ FCF | — | — |
Insufficient data to determine a leader in this category.
Profitability & Efficiency
KYMR leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), KYMR scores 4/9 vs TTRX's 3/9, reflecting mixed financial health.
| Metric | TTRXTurn Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | — | -25.0% |
| ROA (TTM)Return on assets | -87.1% | -22.3% |
| ROICReturn on invested capital | — | -24.9% |
| ROCEReturn on capital employed | -125.5% | -27.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.05x |
| Net DebtTotal debt minus cash | -$751,563 | -$275M |
| Cash & Equiv.Liquid assets | $872,599 | $357M |
| Total DebtShort + long-term debt | $121,036 | $82M |
| Interest CoverageEBIT ÷ Interest expense | — | -2119.53x |
KYMR leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
KYMR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KYMR five years ago would be worth $19,212 today (with dividends reinvested), compared to $5,421 for TTRX. Over the past 12 months, KYMR leads with a +190.7% total return vs TTRX's -45.8%. The 3-year compound annual growth rate (CAGR) favors KYMR at 45.0% vs TTRX's -18.5% — a key indicator of consistent wealth creation.
| Metric | TTRXTurn Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -19.1% | +16.3% |
| 1-Year ReturnPast 12 months | -45.8% | +190.7% |
| 3-Year ReturnCumulative with dividends | -45.8% | +205.1% |
| 5-Year ReturnCumulative with dividends | -45.8% | +92.1% |
| 10-Year ReturnCumulative with dividends | -45.8% | +154.4% |
| CAGR (3Y)Annualised 3-year return | -18.5% | +45.0% |
KYMR leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
KYMR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KYMR is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than TTRX's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 82.2% from its 52-week high vs TTRX's 14.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TTRXTurn Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.45x | 1.03x |
| 52-Week HighHighest price in past year | $26.50 | $103.00 |
| 52-Week LowLowest price in past year | $2.57 | $28.06 |
| % of 52W HighCurrent price vs 52-week peak | +14.3% | +82.2% |
| RSI (14)Momentum oscillator 0–100 | 61.1 | 54.1 |
| Avg Volume (50D)Average daily shares traded | 23K | 602K |
KYMR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TTRX as "Buy" and KYMR as "Buy".
| Metric | TTRXTurn Therapeutics… | KYMRKymera Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $118.06 |
| # AnalystsCovering analysts | 1 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KYMR leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns.
Best OverallKymera Therapeutics, Inc. (KYMR)Leads 3 of 6 categories
Loading custom metrics...
TTRX vs KYMR: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is TTRX or KYMR a better buy right now?
Analysts rate Turn Therapeutics Inc.
(TTRX) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TTRX or KYMR?
Over the past 5 years, Kymera Therapeutics, Inc.
(KYMR) delivered a total return of +92. 1%, compared to -45. 8% for Turn Therapeutics Inc. (TTRX). Over 10 years, the gap is even starker: KYMR returned +158. 8% versus TTRX's -45. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TTRX or KYMR?
By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.
(KYMR) is the lower-risk stock at 1. 03β versus Turn Therapeutics Inc. 's 1. 45β — meaning TTRX is approximately 41% more volatile than KYMR relative to the S&P 500.
04Which has better profit margins — TTRX or KYMR?
Turn Therapeutics Inc.
(TTRX) is the more profitable company, earning 0. 0% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TTRX leads at 0. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — TTRX or KYMR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is TTRX or KYMR better for a retirement portfolio?
For long-horizon retirement investors, Kymera Therapeutics, Inc.
(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +158. 8% 10Y return). Both have compounded well over 10 years (KYMR: +158. 8%, TTRX: -45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between TTRX and KYMR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.